Ocera Therapeutics
Palo Alto
About Ocera Therapeutics
Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $97.0M
- Funding stage: M&A
- Last round: Post-IPO Debt (Aug 2015)
- Ticker: nasdaq:OCRX
- Website: ocerainc.com
- Phone: 650-475-0158
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ocera-therapeutics-311841 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.